US Patent

US12460206 — PCSK9 iRNA compositions and methods of use thereof

Composition of Matter · Assigned to Alnylam Pharmaceuticals Inc · Expires 2034-08-18 · 8y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects RNAi agents targeting the PCSK9 gene and methods of using them to inhibit PCSK9 expression and treat lipid disorders.

USPTO Abstract

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.

Drugs covered by this patent

Patent Metadata

Patent number
US12460206
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-08-18
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.